[1]
Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc., 1964, 86, 1646-1647.
[2]
Devane, W.A.; Dysarz, F.A., III; Johnson, M.R.; Melvin, L.S.; Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34(5), 605-613.
[3]
Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346(6284), 561-564.
[4]
Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
[5]
Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
[6]
Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50(1), 83-90.
[7]
Cravatt, B.F.; Giang, D.K.; Mayfield, S.P.; Boger, D.L.; Lerner, R.A.; Gilula, N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 1996, 384(6604), 83-87.
[8]
Dinh, T.P.; Kathuria, S.; Piomelli, D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol., 2004, 66(5), 1260-1264.
[9]
Deutsch, D.G.; Chin, S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol., 1993, 46(5), 791-796.
[10]
Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J-C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372(6507), 686-691.
[11]
Zygmunt, P.M.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sørgård, M.; Di Marzo, V.; Julius, D.; Högestätt, E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400(6743), 452-457.
[12]
Smart, D.; Gunthorpe, M.J.; Jerman, J.C.; Nasir, S.; Gray, J.; Muir, A.I.; Chambers, J.K.; Randall, A.D.; Davis, J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 2000, 129(2), 227-230.
[13]
Price, M.R.; Baillie, G.L.; Thomas, A.; Stevenson, L.A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R.G.; Ross, R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol., 2005, 68(5), 1484-1495.
[14]
Pertwee, R.G.; Howlett, A.C.; Abood, M.E.; Alexander, S.P.H.; Di Marzo, V.; Elphick, M.R.; Greasley, P.J.; Hansen, H.S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev., 2010, 62(4), 588-631.
[15]
Mackie, K.; Devane, W.A.; Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol., 1993, 44(3), 498-503.
[16]
Burkey, T.H.; Quock, R.M.; Consroe, P.; Ehlert, F.J.; Hosohata, Y.; Roeske, W.R.; Yamamura, H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol., 1997, 336(2-3), 295-298.
[17]
Glass, M.; Northup, J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol., 1999, 56(6), 1362-1369.
[18]
Twitchell, W.; Brown, S.; Mackie, K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol., 1997, 78(1), 43-50.
[19]
Morisset, V.; Urban, L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J. Neurophysiol., 2001, 86(1), 40-48.
[20]
Svízenská, I.; Dubový, P.; Sulcová, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol. Biochem. Behav., 2008, 90(4), 501-511.
[21]
Savinainen, J.R.; Järvinen, T.; Laine, K.; Laitinen, J.T. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol., 2001, 134(3), 664-672.
[22]
Gonsiorek, W.; Lunn, C.; Fan, X.; Narula, S.; Lundell, D.; Hipkin, R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol., 2000, 57(5), 1045-1050.
[23]
Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 1995, 215(1), 89-97.
[24]
Sugiura, T.; Kishimoto, S.; Oka, S.; Gokoh, M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res., 2006, 45(5), 405-446.
[25]
Cristino, L.; de Petrocellis, L.; Pryce, G.; Baker, D.; Guglielmotti, V.; Di Marzo, V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139(4), 1405-1415.
[26]
Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152(7), 1092-1101.
[27]
Roberts, L.A.; Christie, M.J.; Connor, M. Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br. J. Pharmacol., 2002, 137(4), 421-428.
[28]
Sharir, H.; Console-Bram, L.; Mundy, C.; Popoff, S.N.; Kapur, A.; Abood, M.E. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J. Neuroimmune Pharmacol., 2012, 7(4), 856-865.
[29]
Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA, 2001, 98(7), 3662-3665.
[30]
Porter, A.C.; Sauer, J.M.; Knierman, M.D.; Becker, G.W.; Berna, M.J.; Bao, J.; Nomikos, G.G.; Carter, P.; Bymaster, F.P.; Leese, A.B.; Felder, C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301(3), 1020-1024.
[31]
Bisogno, T.; Melck, D. Bobrov MYu; Gretskaya, N.M.; Bezuglov, V.V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 2000, 351(Pt 3), 817-824.
[32]
Steffens, M.; Zentner, J.; Honegger, J.; Feuerstein, T.J. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem. Pharmacol., 2005, 69(1), 169-178.
[33]
Shoemaker, J.L.; Joseph, B.K.; Ruckle, M.B.; Mayeux, P.R.; Prather, P.L. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther., 2005, 314(2), 868-875.
[34]
Huang, S.M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T.J.; Krey, J.F.; Chu, C.J.; Miller, J.D.; Davies, S.N.; Geppetti, P.; Walker, J.M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA, 2002, 99(12), 8400-8405.
[35]
Fawley, J.A.; Hofmann, M.E.; Andresen, M.C. Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission. J. Neurosci., 2014, 34(24), 8324-8332.
[36]
Brown, I.; Cascio, M.G.; Rotondo, D.; Pertwee, R.G.; Heys, S.D.; Wahle, K.W.J. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog. Lipid Res., 2013, 52(1), 80-109.
[37]
Gabrielsson, L.; Mattsson, S.; Fowler, C.J. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br. J. Clin. Pharmacol., 2016, 82(4), 932-942.
[38]
Ahmad, A.; Crupi, R.; Impellizzeri, D.; Campolo, M.; Marino, A.; Esposito, E.; Cuzzocrea, S. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav. Immun., 2012, 26(8), 1310-1321.
[39]
Petrosino, S.; Cristino, L.; Karsak, M.; Gaffal, E.; Ueda, N.; Tüting, T.; Bisogno, T.; De Filippis, D.; D’Amico, A.; Saturnino, C.; Orlando, P.; Zimmer, A.; Iuvone, T.; Di Marzo, V. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy, 2010, 65(6), 698-711.
[40]
Borrelli, F.; Romano, B.; Petrosino, S.; Pagano, E.; Capasso, R.; Coppola, D.; Battista, G.; Orlando, P.; Di Marzo, V.; Izzo, A.A. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol., 2015, 172(1), 142-158.
[41]
Pessina, F.; Capasso, R.; Borrelli, F.; Aveta, T.; Buono, L.; Valacchi, G.; Fiorenzani, P.; Di Marzo, V.; Orlando, P.; Izzo, A.A. Protective effect of palmitoylethanolamide in a rat model of cystitis. J. Urol., 2015, 193(4), 1401-1408.
[42]
De Petrocellis, L.; Di Marzo, V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 23(1), 1-15.
[43]
Grotenhermen, F.; Russo, E. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential, 1st ed; Haworth Press, Inc.: New York, 2002.
[44]
De Petrocellis, L.; Ligresti, A.; Moriello, A.S.; Allarà, M.; Bisogno, T.; Petrosino, S.; Stott, C.G.; Di Marzo, V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol., 2011, 163(7), 1479-1494.
[45]
De Petrocellis, L.; Orlando, P.; Moriello, A.S.; Aviello, G.; Stott, C.; Izzo, A.A.; Di Marzo, V. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. (Oxf.), 2012, 204(2), 255-266.
[46]
Pertwee, R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem., 2010, 17(14), 1360-1381.
[47]
Silverberg, L.J. Synthesis of Cannabinoids. U. S. Patent 7,186,850, March 6 2007.
[48]
Hippalgaonkar, K.; Gul, W.; ElSohly, M.A.; Repka, M.A.; Majumdar, S. Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins. AAPS PharmSciTech, 2011, 12(2), 723-731.
[49]
Showalter, V.M.; Compton, D.R.; Martin, B.R.; Abood, M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 1996, 278(3), 989-999.
[50]
Thomas, A.; Baillie, G.L.; Phillips, A.M.; Razdan, R.K.; Ross, R.A.; Pertwee, R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol., 2007, 150(5), 613-623.
[51]
McPartland, J.M.; Duncan, M.; Di Marzo, V.; Pertwee, R.G. Are cannabidiol and (Δ9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol., 2015, 172(3), 737-753.
[52]
Ibeas Bih, C.; Chen, T.; Nunn, A.V.W.; Bazelot, M.; Dallas, M.; Whalley, B.J. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 2015, 12(4), 699-730.
[53]
Friedman, D.; Devinsky, O. Cannabinoids in the treatment of epilepsy. N. Engl. J. Med., 2015, 373(11), 1048-1058.
[54]
Riedel, G.; Fadda, P.; McKillop-Smith, S.; Pertwee, R.G.; Platt, B.; Robinson, L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br. J. Pharmacol., 2009, 156(7), 1154-1166.
[55]
Bolognini, D.; Costa, B.; Maione, S.; Comelli, F.; Marini, P.; Di Marzo, V.; Parolaro, D.; Ross, R.A.; Gauson, L.A.; Cascio, M.G.; Pertwee, R.G. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br. J. Pharmacol., 2010, 160(3), 677-687.
[56]
Romano, B.; Pagano, E.; Orlando, P.; Capasso, R.; Cascio, M.G.; Pertwee, R.; Marzo, V.D.; Izzo, A.A.; Borrelli, F. Pure Δ9- tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol. Res., 2016, 113(Pt A), 199-208.
[57]
Appendino, G.; Giana, A.; Gibbons, S.; Maffeic, M.; Gnavic, G.; Grassi, G.; Sterner, O. A Polar Cannabinoid from Cannabis sativa var. Carma. Nat. Prod. Communic., 2008, 3, 1977-1980.
[58]
Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M.M. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J. Nat. Prod., 2008, 71(8), 1427-1430.
[59]
Radwan, M.M.; Elsohly, M.A.; Slade, D.; Ahmed, S.A.; Khan, I.A.; Ross, S.A. Biologically active cannabinoids from high-potency Cannabis sativa. J. Nat. Prod., 2009, 72(5), 906-911.
[60]
Taglialatela-Scafati, O.; Pagani, A.; Scala, F.; De Petrocellis, L.; Di Marzo, V.; Grassi, G.; Giovanni, G.; Appendino, G. Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. Eur. J. Org. Chem., 2010, 11, 2067-2072.
[61]
Radwan, M.M.; ElSohly, M.A.; El-Alfy, A.T.; Ahmed, S.A.; Slade, D.; Husni, A.S.; Manly, S.P.; Wilson, L.; Seale, S.; Cutler, S.J.; Ross, S.A. Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa. J. Nat. Prod., 2015, 78(6), 1271-1276.
[62]
Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54(2), 161-202.
[63]
Bow, E.W.; Rimoldi, J.M. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect. Medicin. Chem., 2016, 8, 17-39.
[64]
Rioli, V.; Gozzo, F.C.; Heimann, A.S.; Linardi, A.; Krieger, J.E.; Shida, C.S.; Almeida, P.C.; Hyslop, S.; Eberlin, M.N.; Ferro, E.S. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. J. Biol. Chem., 2003, 278(10), 8547-8555.
[65]
Dale, C.S. Pagano, Rde.L.; Rioli, V.; Hyslop, S.; Giorgi, R.; Ferro, E.S. Antinociceptive action of hemopressin in experimental hyperalgesia. Peptides, 2005, 26(3), 431-436.
[66]
Heimann, A.S.; Gomes, I.; Dale, C.S.; Pagano, R.L.; Gupta, A.; de Souza, L.L.; Luchessi, A.D.; Castro, L.M.; Giorgi, R.; Rioli, V.; Ferro, E.S.; Devi, L.A. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl. Acad. Sci. USA, 2007, 104(51), 20588-20593.
[67]
Macedonio, G.; Stefanucci, A.; Maccallini, C.; Mirzaie, S.; Novellino, E.; Mollica, A. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools. Protein Pept. Lett., 2016, 23(12), 1045-1051.
[68]
Dodd, G.T.; Mancini, G.; Lutz, B.; Luckman, S.M. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J. Neurosci., 2010, 30(21), 7369-7376.
[69]
Ferrante, C.; Recinella, L.; Leone, S.; Chiavaroli, A.; Di Nisio, C.; Martinotti, S.; Mollica, A.; Macedonio, G.; Stefanucci, A.; Dvorácskó, S.; Tömböly, C.; De Petrocellis, L.; Vacca, M.; Brunetti, L.; Orlando, G. Anorexigenic effects induced by RVD-hemopressin(α) administration. Pharmacol. Rep., 2017, 69(6), 1402-1407.
[70]
Toniolo, E.F.; Maique, E.T.; Ferreira, W.A., Jr; Heimann, A.S.; Ferro, E.S.; Ramos-Ortolaza, D.L.; Miller, L.; Devi, L.A.; Dale, C.S. Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats. Peptides, 2014, 56, 125-131.
[71]
Scrima, M.; Di Marino, S.; Grimaldi, M.; Mastrogiacomo, A.; Novellino, E.; Bifulco, M.; D’Ursi, A.M. Binding of the hemopressin peptide to the cannabinoid CB1 receptor: structural insights. Biochemistry, 2010, 49(49), 10449-10457.
[72]
Bomar, M.G.; Galande, A.K. Modulation of the cannabinoid receptors by hemopressin peptides. Life Sci., 2013, 92(8-9), 520-524.
[73]
Gomes, I.; Grushko, J.S.; Golebiewska, U.; Hoogendoorn, S.; Gupta, A.; Heimann, A.S.; Ferro, E.S.; Scarlata, S.; Fricker, L.D.; Devi, L.A. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J., 2009, 23(9), 3020-3029.
[74]
Bomar, M.G.; Samuelsson, S.J.; Kibler, P.; Kodukula, K.; Galande, A.K. Hemopressin forms self-assembled fibrillar nanostructures under physiologically relevant conditions. Biomacromolecules, 2012, 13(3), 579-583.
[75]
Leone, S.; Recinella, L.; Chiavaroli, A.; Martinotti, S.; Ferrante, C.; Mollica, A.; Macedonio, G.; Stefanucci, A.; Dvorácskó, S.; Tömböly, C.; De Petrocellis, L.; Vacca, M.; Brunetti, L.; Orlando, G. Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats. Pharmacol. Rep., 2017, 69(6), 1247-1253.
[76]
Fogaça, M.V.; Sonego, A.B.; Rioli, V.; Gozzo, F.C.; Dale, C.S.; Ferro, E.S.; Guimarães, F.S. Anxiogenic-like effects induced by hemopressin in rats. Pharmacol. Biochem. Behav., 2015, 129, 7-13.
[77]
Petrucci, V.; Chicca, A.; Glasmacher, S.; Paloczi, J.; Cao, Z.; Pacher, P.; Gertsch, J. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci. Rep., 2017, 7(1), 9560.
[78]
Rios, M.Y. Natural Alkamides: Pharmacology, Chemistry and Distribution. In: ; Vallisuta, O., Olimat, S. M., Drug Discovery; IntechOpen: London, 2012; pp. 1-7-144.
[79]
Raduner, S.; Majewska, A.; Chen, J-Z.; Xie, X-Q.; Hamon, J.; Faller, B.; Altmann, K-H.; Gertsch, J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J. Biol. Chem., 2006, 281(20), 14192-14206.
[80]
Ruiu, S.; Anzani, N.; Orrù, A.; Floris, C.; Caboni, P.; Maccioni, E.; Distinto, S.; Alcaro, S.; Cottiglia, F. N-Alkyl dien- and trienamides from the roots of Otanthus maritimus with binding affinity for opioid and cannabinoid receptors. Bioorg. Med. Chem., 2013, 21(22), 7074-7082.
[81]
Gertsch, J. Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system. Planta Med., 2008, 74(6), 638-650.
[82]
Matovic, N.; Matthias, A.; Gertsch, J.; Raduner, S.; Bone, K.M.; Lehmann, R.P.; Devoss, J.J. Stereoselective synthesis, natural occurrence and CB(2) receptor binding affinities of alkylamides from herbal medicines such as Echinacea sp. Org. Biomol. Chem., 2007, 5(1), 169-174.
[83]
Nicolussi, S.; Viveros-Paredes, J.M.; Gachet, M.S.; Rau, M.; Flores-Soto, M.E.; Blunder, M.; Gertsch, J. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. Pharmacol. Res., 2014, 80, 52-65.
[84]
Yu, S.; Levi, L.; Casadesus, G.; Kunos, G.; Noy, N. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor PPARβ/δ in the brain. J. Biol. Chem., 2014, 289, 12748-12758.
[85]
Nicolussi, S.; Chicca, A.; Rau, M.; Rihs, S.; Soeberdt, M.; Abels, C.; Gertsch, J. Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent. Biochem. Pharmacol., 2014, 92(4), 669-689.
[86]
Sugai, E.; Morimitsu, Y.; Kubota, K. Quantitative analysis of sanshool compounds in Japanese pepper (Xanthoxylum piperitum DC.) and their pungent characteristics. Biosci. Biotechnol. Biochem., 2005, 69(10), 1958-1962.
[87]
Sugai, E.; Morimitsu, Y.; Iwasaki, Y.; Morita, A.; Watanabe, T.; Kubota, K. Pungent qualities of sanshool-related compounds evaluated by a sensory test and activation of rat TRPV1. Biosci. Biotechnol. Biochem., 2005, 69(10), 1951-1957.
[88]
Dossou, K.S.S.; Devkota, K.P.; Morton, C.; Egan, J.M.; Lu, G.; Beutler, J.A.; Moaddel, R. Identification of CB1/CB2 ligands from Zanthoxylum bungeanum. J. Nat. Prod., 2013, 76(11), 2060-2064.
[89]
Gertsch, J.; Leonti, M.; Raduner, S.; Racz, I.; Chen, J.Z.; Xie, X.Q.; Altmann, K.H.; Karsak, M.; Zimmer, A. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA, 2008, 105(26), 9099-9104.
[90]
Cho, J.Y.; Chang, H.J.; Lee, S.K.; Kim, H.J.; Hwang, J.K.; Chun, H.S. Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of beta-caryophyllene, a sesquiterpene. Life Sci., 2007, 80(10), 932-939.
[91]
Bento, A.F.; Marcon, R.; Dutra, R.C.; Claudino, R.F.; Cola, M.; Leite, D.F.; Calixto, J.B. β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am. J. Pathol., 2011, 178(3), 1153-1166.
[92]
Katsuyama, S.; Mizoguchi, H.; Kuwahata, H.; Komatsu, T.; Nagaoka, K.; Nakamura, H.; Bagetta, G.; Sakurada, T.; Sakurada, S. Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. Eur. J. Pain, 2013, 17(5), 664-675.
[93]
Guo, K.; Mou, X.; Huang, J.; Xiong, N.; Li, H. Trans-caryophyllene suppresses hypoxia-induced neuroinflammatory responses by inhibiting NF-κB activation in microglia. J. Mol. Neurosci., 2014, 54(1), 41-48.
[94]
Cheng, Y.; Dong, Z.; Liu, S. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology, 2014, 94(1-2), 1-12.
[95]
Chicca, A.; Caprioglio, D.; Minassi, A.; Petrucci, V.; Appendino, G.; Taglialatela-Scafati, O.; Gertsch, J. Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. ACS Chem. Biol., 2014, 9(7), 1499-1507.
[96]
King, A.R.; Dotsey, E.Y.; Lodola, A.; Jung, K.M.; Ghomian, A.; Qiu, Y.; Fu, J.; Mor, M.; Piomelli, D. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem. Biol., 2009, 16(10), 1045-1052.
[97]
Yang, L.; Li, Y.; Ren, J.; Zhu, C.; Fu, J.; Lin, D.; Qiu, Y. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int. J. Mol. Sci., 2014, 15(8), 13637-13648.
[98]
Liu, J.; Lee, J.; Salazar Hernandez, M.A.; Mazitschek, R.; Ozcan, U. Treatment of obesity with celastrol. Cell, 2015, 161(5), 999-1011.
[99]
Blankman, J.L.; Simon, G.M.; Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol., 2007, 14(12), 1347-1356.
[100]
Ueda, N.; Yamanaka, K.; Yamamoto, S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem., 2001, 276(38), 35552-35557.
[101]
Vázquez, L.H.; Palazon, J.; Navarro-Ocaña, A. The Pentacyclic Triterpenes alpha, beta-amyrins: A Review of Sources and Biological Activities.In: Rao V. Ed.;Phytochemicals – A Global Perspective of Their Role in Nutrition and Health; InTechOpen; Newyork, 2012, pp. 487-502.
[102]
da Silva, K.A.; Paszcuk, A.F.; Passos, G.F.; Silva, E.S.; Bento, A.F.; Meotti, F.C.; Calixto, J.B. Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain, 2011, 152(8), 1872-1887.
[103]
Chicca, A.; Marazzi, J.; Gertsch, J. The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br. J. Pharmacol., 2012, 167(8), 1596-1608.
[104]
Yang, R.; Yuan, B-C.; Ma, Y-S.; Zhou, S.; Liu, Y. The anti-inflammatory activity of licorice, a widely used Chinese herb. Pharm. Biol., 2017, 55(1), 5-18.
[105]
Park, M.; Lee, J-H.; Choi, J.K.; Hong, Y.D.; Bae, I-H.; Lim, K-M.; Park, Y-H.; Ha, H. 18β-glycyrrhetinic acid attenuates anandamide-induced adiposity and high-fat diet induced obesity. Mol. Nutr. Food Res., 2014, 58(7), 1436-1446.
[106]
Lee, Y-J.; Lee, Y.M.; Lee, C-K.; Jung, J.K.; Han, S.B.; Hong, J.T. Therapeutic applications of compounds in the Magnolia family. Pharmacol. Ther., 2011, 130(2), 157-176.
[107]
Rempel, V.; Fuchs, A.; Hinz, S.; Karcz, T.; Lehr, M.; Koetter, U.; Müller, C.E. Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS Med. Chem. Lett., 2012, 4(1), 41-45.
[108]
Fuchs, A.; Rempel, V.; Müller, C.E. The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One, 2013, 8(10), e77739.
[109]
Coppola, M.; Mondola, R. Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence. Med. Hypotheses, 2014, 83(6), 673-676.
[110]
Schuehly, W.; Paredes, J.M.V.; Kleyer, J.; Huefner, A.; Anavi-Goffer, S.; Raduner, S.; Altmann, K-H.; Gertsch, J. Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol., 2011, 18(8), 1053-1064.
[111]
Chicca, A.; Gachet, M.S.; Petrucci, V.; Schuehly, W.; Charles, R-P.; Gertsch, J. 4′-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation. J. Neuroinflammation, 2015, 12, 89.
[112]
Lambert, D.M.; Fowler, C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem., 2005, 48(16), 5059-5087.
[113]
Hussain, H.; Hussain, J.; Al-Harrasi, A.; Green, I.R. Chemistry and biology of the genus Voacanga. Pharm. Biol., 2012, 50(9), 1183-1193.
[114]
Kitajima, M.; Iwai, M.; Kikura-Hanajiri, R.; Goda, Y.; Iida, M.; Yabushita, H.; Takayama, H. Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. Bioorg. Med. Chem. Lett., 2011, 21(7), 1962-1964.
[115]
Gerwick, W.H.; Moore, B.S. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem. Biol., 2012, 19(1), 85-98.
[116]
Han, B.; McPhail, K.L.; Ligresti, A.; Di Marzo, V.; Gerwick, W.H. Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J. Nat. Prod., 2003, 66(10), 1364-1368.
[117]
Montaser, R.; Paul, V.J.; Luesch, H. Marine cyanobacterial fatty acid amides acting on cannabinoid receptors. ChemBioChem, 2012, 13(18), 2676-2681.
[118]
Mevers, E.; Matainaho, T.; Allarà’, M.; Di Marzo, V.; Gerwick, W.H.; Mooreamide, A. Mooreamide A: a cannabinomimetic lipid from the marine cyanobacterium Moorea bouillonii. Lipids, 2014, 49(11), 1127-1132.
[119]
Pereira, A.; Pfeifer, T.A.; Grigliatti, T.A.; Andersen, R.J. Functional cell-based screening and saturation transfer double-difference NMR have identified haplosamate A as a cannabinoid receptor agonist. ACS Chem. Biol., 2009, 4(2), 139-144.
[120]
Chianese, G.; Fattorusso, E.; Taglialatela-Scafati, O.; Bavestrello, G.; Calcinai, B.; Dien, H.A.; Ligresti, A.; Di Marzo, V. Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective cannabinoid CB2 receptor ligand. Steroids, 2011, 76(10-11), 998-1002.
[121]
Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Van Soest, R.W.M.; Heubes, M.; Faulkner, D.J.; Fusetani, N. Isolation and structure elucidation of two phosphorylated sterol sulfates, MT1-MMP inhibitors from a marine sponge Cribrochalina sp.: Revision of the structures of haplosamates A and B. Tetrahedron, 2001, 57, 3885-3890.
[122]
Rigano, D.; Formisano, C.; Taglialatela-Scafati, O. Marine Metabolites Modulating CB Receptors and TRP Channels. Planta Med., 2016, 82(9-10), 761-766.
[123]
Harms, H.; Rempel, V.; Kehraus, S.; Kaiser, M.; Hufendiek, P.; Müller, C.E.; König, G.M. Indoloditerpenes from a marine-derived fungal strain of Dichotomomyces cejpii with antagonistic activity at GPR18 and cannabinoid receptors. J. Nat. Prod., 2014, 77(3), 673-677.
[124]
Elsebai, M.F.; Rempel, V.; Schnakenburg, G.; Kehraus, S.; Müller, C.E.; König, G.M. Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum. ACS Med. Chem. Lett., 2011, 2(11), 866-869.
